Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.67 |
| ▸ | LTA4H | P09960 | 1/20 | 0.67 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.67 |
| ▸ | HTR2A | P28223 | 3/20 | 0.53 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27612134 | 0.82 | LTA4H (0.71) | TRPM8LTA4HPLA2G2AHTR2AHTR6 | |
| SCHEMBL27631230 | 0.82 | LTA4H (0.67) | TRPM8LTA4HPLA2G2AHTR2AHTR6 | |
| SCHEMBL5481516 | 0.81 | LTA4H (0.69) | TRPM8LTA4HPLA2G2AHTR2AHTR6 | |
| SCHEMBL5648360 | 0.81 | LTA4H (0.69) | TRPM8LTA4HPLA2G2AHTR2AHTR6 | |
| SCHEMBL837672 | 0.80 | HTR6 (0.74) | HTR2AHTR6ADRB3KMT2AKDM4E | |
| SCHEMBL30579433 | 0.80 | LTA4H (1.00) | TRPM8LTA4HPLA2G2AHTR2AHTR6 | |
| SCHEMBL5479712 | 0.80 | TRPM8 (0.76) | TRPM8LTA4HPLA2G2AHTR2AHTR6 | |
| SCHEMBL5167328 | 0.80 | LTA4H (1.00) | TRPM8LTA4HPLA2G2AHTR2AHTR6 | |
| SCHEMBL5485080 | 0.80 | LTA4H (0.67) | TRPM8LTA4HPLA2G2AHTR2AHTR6 | |
| SCHEMBL5665629 | 0.79 | LTA4H (0.63) | TRPM8LTA4HPLA2G2AHTR2AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224141-A1 | METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER | STC.UNM (US) | 2011-09-15 | — | — | US | claimed |
| WO-2009148623-A2 | METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER | STC.UNM (US) | 2009-12-10 | — | — | WO | claimed |
| US-9326974-B2 | Methods and related compositions for the treatment of cancer | STC.UNM (US) | 2016-05-03 | — | — | US | disclosed |
| US-20140343347-A1 | METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2014-11-20 | — | — | US | disclosed |
| US-8835506-B2 | Methods and related compositions for the treatment of cancer | STC.UNM (US) | 2014-09-16 | — | — | US | disclosed |
| US-20110224141-A1 | METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER | STC.UNM (US) | 2011-09-15 | — | — | US | disclosed |
| WO-2009148623-A2 | METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER | STC.UNM (US) | 2009-12-10 | — | — | WO | disclosed |
| US-7208505-B2 | β3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 2007-04-24 | — | — | US | disclosed |
| EP-1421078-B1 | INDOLE DERIVATIVES AS BETA-3 ADRENERGIC AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES | LILLY CO ELI (US) | 2006-09-27 | — | — | EP | disclosed |
| US-7087635-B2 | 3-substituted oxindole β3 agonists | ELI LILLY AND COMPANY (US) | 2006-08-08 | — | — | US | disclosed |
| EP-1444224-B1 | 3-SUBSTITUTED OXINDOLE BETA-3 AGONISTS | LILLY CO ELI (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20050159473-A1 | 3-Substituted oxindole beta3 agonists | SALL DANIEL J (US) | 2005-07-21 | — | — | US | disclosed |
| US-6911463-B2 | 3-substituted oxindole β-3 agonists | ELI LILLY AND COMPANY (US) | 2005-06-28 | — | — | US | disclosed |
| US-20050080110-A1 | Beta 3 adrenergic agonists | SALL DANIEL JON (US) | 2005-04-14 | — | — | US | disclosed |
| US-20040242668-A1 | 3-substituted oxindole beta-3 agonists | SALL DANIEL JON (US) | 2004-12-02 | — | — | US | disclosed |
| EP-1444224-A2 | 3-SUBSTITUTED OXINDOLE BETA-3 AGONISTS | ELI LILLY AND COMPANY (US) | 2004-08-11 | — | — | EP | disclosed |
| EP-1421078-A1 | BETA-3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003016307-A1 | β3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
| WO-2003016276-A2 | 3-SUBSTITUTED OXINDOLE BETA-3 AGONISTS | ELI LILLY AND COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242668-A1 | 3-substituted oxindole beta-3 agonists | ADRB3, ADRB2, ADRB1 | TRPM8 1464/4885LTA4H 1369/4885PLA2G2A 2121/4885 |
| US-20050159473-A1 | 3-Substituted oxindole beta3 agonists | ADRB3, ADRB2, ADRB1 | TRPM8 1455/4885LTA4H 1364/4885PLA2G2A 2376/4885 |
| US-20050080110-A1 | Beta 3 adrenergic agonists | ADRB3, ADRB2, ADRB1 | TRPM8 1769/4885LTA4H 755/4885PLA2G2A 1815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.